SIGA Technologies Inc.

Ladies and gentlemen, greetings and welcome to the CIGA Technologies fourth quarter and full year 2022 earnings conference call. At this time, all participant lines are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. Before we turn the call over to SEGA management, please note that any forward-looking statements made during this call are based on management's current expectation and observations and are subject to risk and uncertainties that could cause actual results to differ from the forward-looking statements. SEGA does not undertake any obligations to update publicly any forward-looking statement to reflect event or changed circumstances after this call. For a discussion of factors that could cause results to differ, please see the company's filings with the Securities and Exchange Commission, including without limitation the company's annual report on Form 10-K for the year ended December 31, 2022, and its subsequent reports on Form 10-Q and Form 8-K. It is now my pleasure to introduce you to Phil Gomez, CEO. Please go ahead.

Thank you for taking the time to join today's call. Today I'm joined by Dan Luckshire, our CFO. We are pleased to have this opportunity to provide a business and financial update to our shareholders. We'll then be happy to take questions. I'd like to start the call by recapping annual performance for 2022. On our prior year and investor call in March of 2022, we highlighted that 2022 would be a transition year. with no significant expirations of oral TPOX in the U.S. Strategic National Stockpile, or SNS. I'm pleased to report we ended this past year with approximately $111 million in revenue for the year, thanks to a diversification of our revenue base. This diversification has been years in the making, and as a result, we were prepared to respond to the global MPOX or monkeypox outbreak. Our preparation included approval for treatment of MPOX by the EMA in January of 2022, and our proactive build of inventory to be able to deliver TPOCs immediately to customers. Overall, 2022 revenues included $71 million of sales to more than 10 international customers, the first sale of intravenous formulation of TPOCs to the U.S. government, and the first sales totaling approximately $7 million of oral TPOCs to the U.S. Department of Defense. As a frame of reference, prior to 2022, the company had only one international customer, cumulative international sales of approximately $15 million over the two-year time period of 2020 and 2021, and it only sold oral teapots to one buyer within the U.S. government. Additionally, it should be noted that 2022 was the first year since the start of teapot deliveries in 2013 in which the company had substantial positive cash flows without the benefit of any sales of oral teapots to the Strategic National Stockpile. We believe the trend of financial diversification at CIGA emphasizes a growing recognition by governments in different regions of the world of the overall importance of health security preparedness. As noted in our last investment call in November, we believe that broadened procurement of TPOCs is being generally driven by a combination of CIGA business development activities and long-term trends that have been building for a while. Specifically in connection with 2022 sales of TPox, we believe the diversification of international sales was at least partly driven by the initial government responses to the 2022 MPox outbreak. With respect to the MPox outbreak, in which there have been approximately 86,000 global cases and 30,000 U.S. cases since May of 2022, the outbreak has highlighted the importance of TPox, given that TPox was used to compassionately treat more than 6,500 MPox cases in the U.S., In many cases internationally, and approximately seven clinical trials have been launched, as well as another four are scheduled to be launched to study the use of TPOX for MPOX, many of which are randomized placebo-controlled trials that are sponsored by government agencies or NGOs. To reiterate what I said in the November investor call with regard to the trials, the timing and the ultimate number of participants of the trials will depend on the path of the MPOX outbreak and the general speed of enrollment. Hence, the timing and the likely ultimate enrollment levels of these trials, especially the randomized placebo-controlled trials, continues to be currently unknown. In turn, this means the timing and composition of an FDA submission for an MPOX label for TBOX is also currently unknown. While it should be acknowledged that global cases have significantly decreased since the third quarter of 2022, we continue to believe that it is likely that MPOX will continue to have a global presence going forward. While the short-term path of the MPOCS outbreak is uncertain, what we have seen and learned to date indicates there is a high probability that the United States and other countries across the world will have to deal with MPOCS cases in the future. It is just unknown as to the ultimate magnitude of the cases, the scope of the cases across different communities, and whether case levels become consistent or whether case levels come and go periodically. We believe that in most scenarios, there will be a need for TPoCS. Looking forward, we expect the company's streak of positive financial performance will continue into 2023 and 2024. We believe a key driver for sales during this period will be procurement by the U.S. government. There are two key reasons for our view. First, it should be noted that while there were no scheduled TPOCs expirations in the Strategic National Stockpile during 2022, we estimate there will be substantial TPOCs product expirations in the Strategic National Stockpile during 2023 and 2024. As a reminder, when BARDA issued the 19C contract in 2018, it contained four procurement options for oral TPOX, in which each option was valued at approximately $112.5 million. Oral TPOX has a seven-year shelf life, and as we saw in 2020 and 2021, BARDA exercised procurement options as stockpiled product that had been manufactured in 2013 and 2014 expired. In substance, we replenished the U.S. government stockpile with deliveries of oral TPOX in those calendar years. As such, with the scheduled expiration of a substantial number of stockpile teapot courses in 2023 and 2024, such courses being manufactured in 2016 and 2017, we believe the U.S. government will order a substantial amount of oral teapots in 2023. We expect to get a more specific view of the likely order size in the second quarter. Additionally, we believe the U.S. government would need to exercise procurement options under the 19C contract in 2024, or make orders under a new procurement contract in order to at least maintain historical unexpired TPOC levels within the strategic national stockpile. A second key reason we believe the U.S. government sales will be a substantial source of revenue in the near term is that, in addition to the company working with the Administration for Strategic Preparedness and Response, or ASPR, the S&S and BARDA to get options exercised under the 19-C contract, We've continued to engage stakeholders on the benefits of a long-term, 10-year contract with annual options to smooth out deliveries and better manage budgets and supply chains. And as a part of this conversation about a new contract, we've been focused on ensuring that the requirements for post-exposure prophylaxis, or PEP, use of TPOCs are also considered by the U.S. government. As a quick reminder, PEP has an expected 28-day course regimen, which contrasts with a 14-day regimen for the treatment indications. This difference would require a substantial increase in procurement and stockpiling in order to fully protect 1.7 million Americans, which is the targeted number of courses noted in prior government RFPs. In terms of the ultimate sizing of the stockpile as stated in prior investor calls, we believe that clinical results from the PEP program could play an important role. On this front, I am pleased to report that the PEP clinical trials made substantial progress over the last 12 months, with the immunogenicity trial recently completing enrollment and the expanded safety trial on track to meet target enrollment in March of this year. Currently, we are performing the immunogenicity testing of the patient samples from the TPOX-GENIOS immunogenicity study. Going forward, we are targeting a data readout in connection with the immunogenicity trial within the next 90 days. At the next investor call, Dr. Dennis Ruby, our chief scientific officer, will join the call to provide a more detailed update on the PEP program. The goal for the PEP program is to make an FDA submission in early 2024 for a PEP label expansion for oral TPOX. I'd like to highlight that a PEP label expansion for oral TPOX would continue an impressive regulatory streak for SIGA. Since the beginning of 2022, the company has achieved regulatory approvals from the EMA in continental Europe and the MHRA of the United Kingdom for a broad indication for oral TPOX for the treatment of smallpox, MPOX, cowpox, in vaccinia complications following vaccination against smallpox. Additionally, we achieved regulatory approval in May 2022 from the FDA for the intravenous formulation of TPOX for the treatment of smallpox. At this point, I'd like to hand the call over to Dan for the financial update.

Thanks, Bill. For the 12 months ended December 31st, 2022, DIGA's revenue was approximately $111 million. of which approximately $71 million of revenue relates to international oral TPOX sales. Another $7 million approximately of revenue relates to sales of oral TPOX to the U.S. Department of Defense. And a further $7 million approximately of revenue relates to the first sale of IV TPOX to the U.S. government. The remaining revenue is approximately $26 million mostly relate to research and development and supportive activities. To reiterate Phil's earlier comments, 2022 revenues represent a meaningful expansion of the TPOC's revenue base with more than 10 new international customers from a narrow base prior to 2022 and the first sales of oral TPOCs to the U.S. Department of Defense and the first sale of IV TPOCs to the U.S. government. For 2023, we will continue to work on generating revenues from the expanded international customer base while also procuring replenishment or pursuing replenishment of the U.S. government stockpile and resumption of substantial sales to the U.S. government under the 19 contract. Furthermore, we will continue to work with the U.S. Department of Defense on potential additional procurement orders and or contracts to coordinate additional deliveries of IV TPOCs to the strategic national stockpile in connection with the 2022 IV option exercise under the 19C contract, and to pursue a new contract with the U.S. government through the administration of strategic preparedness and response. Returning to the 2022 financial results, pre-tax operating income for the year which excludes other income, taxes, and adjustments to the fair value of the warrant, was approximately $43 million. Net income for 2022 was approximately $34 million. And fully diluted income per share was 46 cents. At December 31st, 2022, the cash balance for the company was approximately $99 million. For the full year 2022, the company used approximately $46 million for capital management activities. Approximately $33 million was used for a 45 cents per share special cash dividend that was paid in June of 2022. And approximately $13 million was used to repurchase approximately 1.8 million shares of common stock. Please note that, as mentioned on prior investor calls, In addition to using cash for capital management activities, the company has been using cash to proactively build work in process inventory, as well as final drug product inventory. This concludes the financial update. At this point, I'll turn the call back to Phil.